Vion Pharmaceuticals To Present Data On Onrigin(TM)at The ASCO(R) Annual Meeting

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

More: continued here

Filed under: Clinical Trials on June 1st, 2009